Remdesivir for 5 or 10 Days in Patients with Severe Covid-19

A randomized trial comparing a 5-day course of intravenous remdesivir with a 10-day course in patients with Covid-19 pneumonia and hypoxemia who were not yet receiving mechanical ventilation showed no significant differences in outcome related to the duration of treatment.

Saved in:
Bibliographic Details
Published inThe New England journal of medicine Vol. 383; no. 19; pp. 1827 - 1837
Main Authors Goldman, Jason D, Lye, David C.B, Hui, David S, Marks, Kristen M, Bruno, Raffaele, Montejano, Rocio, Spinner, Christoph D, Galli, Massimo, Ahn, Mi-Young, Nahass, Ronald G, Chen, Yao-Shen, SenGupta, Devi, Hyland, Robert H, Osinusi, Anu O, Cao, Huyen, Blair, Christiana, Wei, Xuelian, Gaggar, Anuj, Brainard, Diana M, Towner, William J, Muñoz, Jose, Mullane, Kathleen M, Marty, Francisco M, Tashima, Karen T, Diaz, George, Subramanian, Aruna
Format Journal Article
LanguageEnglish
Published United States Massachusetts Medical Society 05.11.2020
Subjects
Adenosine Monophosphate - administration & dosage
Adenosine Monophosphate - adverse effects
Adenosine Monophosphate - analogs & derivatives
Adult
Aged
Alanine
Alanine - administration & dosage
Alanine - adverse effects
Alanine - analogs & derivatives
Alanine transaminase
Animal models
Antiviral activity
Antiviral Agents - administration & dosage
Antiviral Agents - adverse effects
Antiviral drugs
Betacoronavirus
Confidence intervals
Constipation
Coronavirus Infections - drug therapy
Coronavirus Infections - mortality
Coronavirus Infections - therapy
Coronaviruses
COVID-19
Creatinine
Disease
DNA-directed RNA polymerase
Drug Administration Schedule
Female
Hospitalization
Humans
Intravenous administration
Male
Mechanical ventilation
Middle Aged
Nausea
Original
Oxygen Inhalation Therapy
Pandemics
Patients
Pneumonia, Viral - drug therapy
Pneumonia, Viral - mortality
Pneumonia, Viral - therapy
Respiratory failure
SARS-CoV-2
Severe acute respiratory syndrome coronavirus 2
Treatment Outcome
United States > US
Online AccessGet full text

Cover

More Information
Summary:A randomized trial comparing a 5-day course of intravenous remdesivir with a 10-day course in patients with Covid-19 pneumonia and hypoxemia who were not yet receiving mechanical ventilation showed no significant differences in outcome related to the duration of treatment.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 14
content type line 23
ObjectType-Undefined-3
A list of investigators in the GS-US-540-5773 trial is provided in the Supplementary Appendix, available at NEJM.org.
ISSN:0028-4793
1533-4406
1533-4406
DOI:10.1056/NEJMoa2015301